601 reports of this reaction
6.5% of all IVACAFTOR reports
#2 most reported adverse reaction
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is the #2 most commonly reported adverse reaction for IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 601 FDA adverse event reports linking IVACAFTOR to INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS. This represents approximately 6.5% of all 9,200 adverse event reports for this drug.
Patients taking IVACAFTOR who experience infective pulmonary exacerbation of cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is moderately reported among IVACAFTOR users, representing a notable but not dominant share of adverse events.
In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported for IVACAFTOR:
The following drugs have also been linked to infective pulmonary exacerbation of cystic fibrosis in FDA adverse event reports:
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS has been reported as an adverse event in 601 FDA reports for IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS accounts for approximately 6.5% of all adverse event reports for IVACAFTOR, making it one of the most commonly reported side effect.
If you experience infective pulmonary exacerbation of cystic fibrosis while taking IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.